Pre-launch · We're opening Reserve Meds to a limited first cohort. Join the waitlist ›

Avmapki Fakzynja Co‑Pack in Saudi Arabia

How patients in Saudi Arabia access Avmapki Fakzynja Co‑Pack (vemurafenib + cobimetinib) via Named Patient Program.

Avmapki Fakzynja Co‑Pack - overview

Avmapki Fakzynja Co‑Pack (vemurafenib + cobimetinib) is manufactured by Genentech / Roche (verify co-pack) and indicated for BRAF+ melanoma. It is an oral co-pack, avutometinib (RAF/MEK clamp) + defactinib (FAK inhibitor), twice-weekly + twice-daily dosing cycles approved by the US FDA in 2025 and may be accessible to patients in Saudi Arabia through a Named Patient Program or personal-import pathway.

Access in Saudi Arabia

The Saudi Food and Drug Authority (SFDA) operates a Personal Import / Unregistered Medicine pathway for named patients, typically requiring physician justification and hospital ethics-committee review.

How Reserve Meds coordinates access in Saudi Arabia

  1. Patient or treating physician submits a request.
  2. We verify clinical appropriateness and Saudi Arabia-specific eligibility.
  3. Treating physician in Saudi Arabia issues prescription and clinical justification.
  4. Country-specific NPP/personal-import forms are prepared and filed.
  5. We source Avmapki Fakzynja Co‑Pack from a DSCSA-compliant US specialty wholesaler.
  6. Cold-chain shipment to the patient's physician or hospital pharmacy in Saudi Arabia.

Typical timeline for Saudi Arabia

End-to-end, most requests are completed in 2-6 weeks. Saudi Arabia's tier 1 regulatory maturity typically supports fast processing times.

What patients and physicians in Saudi Arabia ask

  • Is the pathway legal in Saudi Arabia? Yes - it operates under Saudi Arabia's established NPP or personal-import framework.
  • Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
  • What physician credentials do I need? A licensed physician in Saudi Arabia able to issue the prescription and clinical justification.
  • What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
  • Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Avmapki Fakzynja Co‑Pack in Saudi Arabia

Request Avmapki Fakzynja Co‑Pack

YELLOW
AI Regulatory Review Agent, preliminary signal
Small-molecule specialty drug. Saudi Arabia (SFDA) named-patient pathway generally supports oral specialty drugs; HRD flag requires one-time per-patient registry check.
Rule: sm_specialty_to_hrd_review • Reviewed 2026-04-22

Join the waitlist

Review & oversight. Content on this page is reviewed by Reserve Meds's clinical and regulatory team. A US-licensed pharmacist reviews every prescription before dispensing. Regulatory posture is informational, not legal advice; case-specific questions route to retained outside counsel. Review methodology ›
Last medically reviewed: .